A recent paper, currently available on bioRxiv* preprint server, reveals the potential for a common class of public antibodies to develop broad cross-neutralization against the severe acute ...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve at a rapid pace, generating new variants that arouse concern. Variants that were first detected in California (B.1.429 ...
Therefore, we administered a third 30-μg BNT162b2 dose 7.9 to 8.8 months after dose 2 to 11 participants 18 to 55 years of age and to 12 participants 65 to 85 years of age from U.S. sites in the phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results